Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Clobetasol

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Dermoval

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 859Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Formosa, Samil Pharma Ink Clobetasol Ophthalmic Drug Deal
    Formosa, Samil Pharma Ink Clobetasol Ophthalmic Drug Deal

    12 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/formosa-pharmaceuticals-announces-licensing-agreement-with-samil-pharmaceuticals-co-ltd-for-commercialization-of-clobetasol-propionate-ophthalmic-suspension-for-the-treatment-of-inflammation-and-pain-following-ocular-surgery-302658104.html

    PR NEWSWIRE
    12 Jan 2026
    Share Share
    Formosa Licenses Clobetasol Ophthalmic Suspension to Rxilient
    Formosa Licenses Clobetasol Ophthalmic Suspension to Rxilient

    03 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/formosa-pharmaceuticals-announces-licensing-agreement-with-rxilient-for-commercialization-of-clobetasol-propionate-ophthalmic-suspension-for-the-treatment-of-inflammation-and-pain-following-ocular-surgery-302631552.html

    PR NEWSWIRE
    03 Dec 2025
    Share Share
    Xiromed’s Generics Clobetasol Propionate Receives Approval in US
    Xiromed’s Generics Clobetasol Propionate Receives Approval in US

    20 Nov 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210638

    FDA
    20 Nov 2025
    Share Share
    Harrow Acquires US Commercial Rights to Byqlovi from Formosa
    Harrow Acquires US Commercial Rights to Byqlovi from Formosa

    10 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250609515264/en/Harrow-Acquires-U.S.-Commercial-Rights-to-BYQLOVI-Clobetasol-Propionate-Ophthalmic-Suspension-0.05-from-Formosa-Pharmaceuticals

    BUSINESSWIRE
    10 Jun 2025
    Share Share
    Formosa, Adalvo License Clobetasol For Eye Conditions
    Formosa, Adalvo License Clobetasol For Eye Conditions

    28 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/formosa-pharmaceuticals-and-adalvo-limited-announce-licensing-agreement-for-clobetasol-propionate-ophthalmic-suspension-for-the-treatment-of-ocular-inflammation-and-pain-302465602.html

    PR NEWSWIRE
    28 May 2025
    Share Share
    Formosa Pharmaceuticals Licenses Clobetasol Propionate to Apotex
    Formosa Pharmaceuticals Licenses Clobetasol Propionate to Apotex

    06 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/formosa-pharmaceuticals-announces-licensing-agreement-with-apotex-inc-for-commercialization-of-clobetasol-propionate-ophthalmic-suspension-for-post-ocular-surgery-inflammation-and-pain-for-mexico-302447818.html

    PR NEWSWIRE
    06 May 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.